Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 5,000 shares of the stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $14.71, for a total transaction of $73,550.00. Following the completion of the sale, the insider now owns 69,184 shares of the company’s stock, valued at approximately $1,017,696.64. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jay Barth also recently made the following trade(s):

  • On Friday, December 1st, Jay Barth sold 5,000 shares of Amicus Therapeutics stock. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded down $0.23 during mid-day trading on Thursday, reaching $15.44. 1,676,325 shares of the company’s stock traded hands, compared to its average volume of 2,419,200. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics, Inc. has a 52 week low of $5.07 and a 52 week high of $16.60. The stock has a market cap of $2,570.00, a PE ratio of -8.44 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. During the same period in the prior year, the business earned ($0.33) EPS. The business’s quarterly revenue was up 419.0% on a year-over-year basis. sell-side analysts predict that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Legal & General Group Plc raised its holdings in shares of Amicus Therapeutics by 1.6% in the 2nd quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock valued at $558,000 after purchasing an additional 852 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Amicus Therapeutics by 5.7% in the 2nd quarter. Amalgamated Bank now owns 18,451 shares of the biopharmaceutical company’s stock valued at $186,000 after purchasing an additional 1,002 shares in the last quarter. Aperio Group LLC raised its holdings in shares of Amicus Therapeutics by 13.5% in the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Amicus Therapeutics by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 138,438 shares of the biopharmaceutical company’s stock valued at $1,394,000 after purchasing an additional 2,690 shares in the last quarter. Finally, Great West Life Assurance Co. Can raised its holdings in shares of Amicus Therapeutics by 40.2% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 4,145 shares in the last quarter.

Several research firms have recently weighed in on FOLD. Chardan Capital reissued a “buy” rating and issued a $16.50 price target (down previously from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Cowen reissued an “outperform” rating and issued a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Leerink Swann reissued an “outperform” rating and issued a $17.00 price target (down previously from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Robert W. Baird reissued an “outperform” rating and issued a $16.00 price target on shares of Amicus Therapeutics in a research note on Monday, September 25th. Finally, Bank of America increased their price target on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $17.81.

ILLEGAL ACTIVITY NOTICE: “Jay Barth Sells 5,000 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/04/jay-barth-sells-5000-shares-of-amicus-therapeutics-inc-fold-stock-2.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.